Monoclonal Antibody Manufacturing

Monoclonal antibodies are among the most important therapeutic modalities in modern medicine, used to treat cancers, autoimmune diseases, and chronic inflammatory disorders. As global demand increases, manufacturers must scale production while maintaining strict control over product quality and regulatory compliance.

ZETA supports monoclonal antibody manufacturers with integrated process systems spanning upstream cell culture and downstream purification. Our engineering expertise enables stable production environments that support high yields, consistent product quality, and scalable biologics manufacturing.

Monoclonal antibodies are used across a wide range of therapeutic areas and represent one of the most rapidly expanding segments of the pharmaceutical industry.

Common applications include:

Monoclonal antibodies are predominantly manufactured using mammalian cell culture systems, with Chinese Hamster Ovary (CHO) cells serving as the industry standard. Successful upstream processing depends on precisely controlled bioreactor environments in which temperature, pH, dissolved oxygen, mixing, and nutrient supply remain stable throughout the production cycle.

Modern upstream platforms are designed to support high cell densities, robust growth, and consistently high antibody titers. This includes both fed batch strategies — the most widely used approach for commercial mAb production — and perfusion processes that enable continuous, long-duration cultivation with steady productivity.
ZETA provides fully engineered upstream solutions and automation capabilities that ensure reliable cell culture performance at scale. Our portfolio includes:

• seed train expansion systems
• media and buffer preparation platforms
• bioreactors and fermentation vessels for mammalian cell culture
• temperature control units
• integrated process monitoring, automation, and control

Together, these technologies form a cohesive upstream ecosystem that maintains stable culture conditions and supports high-performance antibody manufacturing.

Monoclonal antibodies are typically produced using mammalian cell culture systems, with CHO cells as the industry standard. Our integrated systems connect seamlessly with facility infrastructure and digital control architectures, enabling scalable, reliable mAb production from development through commercial manufacturing.